THE COMPREHENSIVE SYSTEMATIC REVIEW OF RECURRENT EPISTAXIS
DOI:
https://doi.org/10.61841/mrcx9w26Keywords:
Epistaxis, recurrent epistaxis, anterior epistaxis, posterior epistaxisAbstract
Background: Epistaxis affects roughly 60% of adults at some point in their lives, yet only about 10% necessitate medical intervention. Recurrent epistaxis remains a frequent reason for emergency department visits and involves multiple risk factors. This study aims to systematically review the literatures on recurrent epistaxis in the last 10 years.
Methods: This systematic review adhered to the PRISMA 2020 standards and included full-text English literature published between 2014 and 2024. Exclusion criteria involved editorials, review articles from the same journal, and submissions lacking a DOI. Literature was gathered from online sources such as PubMed and SagePub.
Result: Our search in PubMed yielded 76 articles, while SagePub produced 2415 articles. Focusing on the last 10 years (2014-2024), PubMed had 57 articles and SagePub had 712 articles. Ultimately we selected 6 papers that met our criteria, 3 from PubMed and 3 from SagePub.
Conclusion: Managing recurrent epistaxis requires detailed examination on risk factors and underlying etiologies. The risk factors for recurrent epistaxis were unidentified bleeding point, blood parameters, the use of antithrombotic agent, and hereditary diseases. The current treatment of recurrent epistaxist can be done with bipolar cauterization and microwave ablation on bleeding points.
References
Ando Y, Iimura J, Arai S, Arai C, Komori M, Tsuyumu M, et al. Risk factors for recurrent epistaxis: Importance of initial treatment. Auris Nasus Larynx [Internet]. 2014 Feb 1 [cited 2024 Feb 15];41(1):41–5. Available from: https://www.sciencedirect.com/science/article/pii/S0385814613001429
Seikaly H. Epistaxis. New England Journal of Medicine [Internet]. 2021 Mar 11 [cited 2024 Feb 15];384(10):944–51. Available from: https://doi.org/10.1056/NEJMcp2019344
Abrich V, Brozek A, Boyle TR, Chyou PH, Yale SH. Risk Factors for Recurrent Spontaneous Epistaxis. Mayo Clinic Proceedings [Internet]. 2014 Dec 1 [cited 2024 Feb 15];89(12):1636–43. Available from: https://www.sciencedirect.com/science/article/pii/S0025619614008349
Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK, et al. Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination. Cell Host Microbe. 2018 Sep 12;24(3):439446.e4.
Ekber Karabulut A, Çevik Y, Emektar E, Kerem Çorbacioğlu Ş, Dağar S, Yardim O. Analysis of mean platelet volume and red blood cell distribution width in recurrent epistaxis. Turkish Journal of Emergency Medicine [Internet]. 2018 Jun 1 [cited 2024 Feb 15];18(2):67–70. Available from: https://www.sciencedirect.com/science/article/pii/S2452247317302832
Lou ZC, Jin KF. Randomized Comparative Study of Microwave Ablation and Electrocautery for Control of Recurrent Epistaxis. Ear Nose Throat J [Internet]. 2021 Aug 1 [cited 2024 Feb 15];100(7):509–15. Available from: https://doi.org/10.1177/0145561319879238
McWilliams JP, Majumdar S, Kim GH, Lee J, Seals K, Tangchaiburana S, et al. North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial. Journal of Thrombosis and Haemostasis [Internet]. 2022 May 1 [cited 2024 Feb 15];20(5):1115–25. Available from: https://www.sciencedirect.com/science/article/pii/S1538783622001568
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
